Gastrin releasing peptide compounds

Details Gastrin releasing peptide compounds Gastrin releasing peptide compounds

2011-04-12

2011-04-12

Jones, D L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C424S009100, C534S014000, C514S002600, C514S009100

Reexamination Certificate

active

07922998

ABSTRACT:
New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure:wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof.Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

REFERENCES:
patent: 4885363 (1989-12-01), Tweedle
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5068222 (1991-11-01), Camble et al.
patent: 5084555 (1992-01-01), Coy et al.
patent: 5217955 (1993-06-01), Bogden et al.
patent: 5244883 (1993-09-01), Cai et al.
patent: 5369094 (1994-11-01), Schally et al.
patent: 5410018 (1995-04-01), Spindel et al.
patent: 5428018 (1995-06-01), Edwards et al.
patent: 5428019 (1995-06-01), Edwards et al.
patent: 5474756 (1995-12-01), Tweedle et al.
patent: 5534497 (1996-07-01), Verbruggen
patent: 5620955 (1997-04-01), Knight et al.
patent: 5620959 (1997-04-01), Leban et al.
patent: 5686410 (1997-11-01), Albert et al.
patent: 5723578 (1998-03-01), Coy et al.
patent: 5833985 (1998-11-01), Ball et al.
patent: 5834433 (1998-11-01), Krstenansky
patent: 5965695 (1999-10-01), Simon et al.
patent: 5981504 (1999-11-01), Buchsbaum et al.
patent: 6075121 (2000-06-01), Simon et al.
patent: 6191290 (2001-02-01), Safavy
patent: 6200546 (2001-03-01), Hoffman et al.
patent: 6307017 (2001-10-01), Coy et al.
patent: 6866837 (2005-03-01), Reubi et al.
patent: 6921526 (2005-07-01), Hoffman et al.
patent: 7060247 (2006-06-01), Hoffman et al.
patent: 7226577 (2007-06-01), Cappelletti et al.
patent: 2002/0164287 (2002-11-01), Rajagopalan
patent: 2002/0176819 (2002-11-01), Hoffman et al.
patent: 2003/0050436 (2003-03-01), Coy et al.
patent: 2003/0171561 (2003-09-01), Pillai et al.
patent: 2003/0224998 (2003-12-01), Reubi et al.
patent: 2004/0136906 (2004-07-01), Cappelletti et al.
patent: 2005/0163710 (2005-07-01), Hoffman et al.
patent: 2005/0171014 (2005-08-01), Tarasova et al.
patent: 2006/0067886 (2006-03-01), Hoffman et al.
patent: 2007/0161047 (2007-07-01), Zhong et al.
patent: 2007/0270575 (2007-11-01), Jakobovits et al.
patent: 2008/0008649 (2008-01-01), Cappelletti et al.
patent: 0309297 (1989-03-01), None
patent: 0436005 (1995-03-01), None
patent: 0489089 (1996-06-01), None
patent: 0438519 (1998-05-01), None
patent: 1181936 (2002-02-01), None
patent: 0749325 (2002-06-01), None
patent: 1001977 (2005-10-01), None
patent: 89/02897 (1989-06-01), None
patent: 90/03980 (1990-04-01), None
patent: WO91/01144 (1991-02-01), None
patent: 91/02746 (1991-03-01), None
patent: 95/24220 (1995-09-01), None
patent: 9532741 (1995-12-01), None
patent: WO96/03427 (1996-02-01), None
patent: 98/47524 (1998-10-01), None
patent: 9847524 (1998-10-01), None
patent: 99/62563 (1999-12-01), None
patent: 0038738 (2000-07-01), None
patent: 00/50059 (2000-08-01), None
patent: 01/52900 (2001-07-01), None
patent: 0152900 (2001-07-01), None
patent: 0162777 (2001-08-01), None
patent: 0287631 (2002-11-01), None
patent: 02087631 (2002-11-01), None
patent: 03/072754 (2003-09-01), None
patent: 2004062574 (2004-07-01), None
patent: 2004065407 (2004-08-01), None
patent: WO2004065407 (2004-08-01), None
Supplementary European Search Report for European Application No. EP04777906, Mailed on Oct. 28, 2008.
Smith et al., “Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: A concise update” Nuclear Medicine and Biology (2003), vol. 30, pp. 861-868.
Hoffman et al., “Novel Series of 111In-Labeled Bombesin Analogs as Potential Radiopharmaceuticals for Specific targeting of Gastin-Releasing Peptide Receptors Expressed on Human Prostate Cancer Cells” Journal of Nuclear Medicine (2003), vol. 44, pp. 823-831.
Rogers et al., “In Vitro and In Vivo Evaluation of a 64Cu-Labeled Polyethylene Glycol-Bombesin Conjugate” Cancer Biotherapy & Radiopharmaceuticals, (2004), vol. 19, No. 1, pp. 25-34.
Internatioanl Search Report and Written Opinion for International Application No. PCT/US07/61813 mailed Mar. 5, 2008.
Hoffman et al. “Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells” Nuclear Medicine & Biology (2001), vol. 28, pp. 527-539.
Smith et al. “Radiochemical investigation of 177 Lu-DOT-8-Aoc-BBN[7-14]NH2: an invitro/invivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells” Nuclear Medicine & Biology, vol. 30, 2003, pp. 101-109.
Safavy et al. “Paclitaxel Derivatives for Targeted Therapy of Cancer: Toward the Development of Smart Taxanes”, J. of Med. Chem., vol. 42, Jan. 1, 1999, pp. 4919-4924.
Wen et al. “poly(ethylen glycol)-conjgated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains”, Bioconjugate chemistry, vol. 12, No. 4, Jul. 1, 2001, pp. 545-553.
Supplementary European Search report for EP 03800223.4 dated Jun. 18, 2009.
Hu et al. “Pm-149 DOTA bombesin analogs for potential radiotherapy-in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH”, Nuclear Medicine and Biology, vol. 29, No. 4, May 1, 2002, pp. 423-430.
Giblin et al. (1998), Proc. Natl. Aca. Sci., USA, vol. 95, pp. 12814-12818.
Walsh et al., Western Journal of Medicine, vol. 155, pp. 152-163, 1991.
Heppeler et al., Receptor Targeting for Tumor Localization and Therapy with Radiopeptides. Current Medicinal Chemistry 2000, 7:971-994.
Sethi et al., Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo, Cancer Res. May 1, 1992;52(9 Suppl):2737s-2742s.
Halmos, T., Wittliff, J.L., and Schally, A.V., Characterization of bombesin/gastrin releasing peptide receptors on human breast cancer and their Relationship to steroid receptor expression, Cancer Research 55:280-287, 1995.
Kelly, K., Kane, M.A., and Bunn, P.A., “Growth factors in lung cancer: Possible etiologic role and clinical target”, Medical and Pediatric Oncology 19:449-458, 1991.
Jensen, R.T., Mrozinski, J.E., and Coy, D.H., “Bombesin receptor antagonists: Different classes and cellular basis of action”, Recent Results in Cancer Research 129:87-113.
Reile, H., Armatis, P.E., and Schally, A.V., Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells, Prostate, Jul. 1994;25(1):29-38.
Schutte, J., and Seeber, S., “Bombesin antagonists: Experimental and clinical results”, Recent Results in Cancer Research 129:115-129, 1993.
Walsh, J.H., Karnes, W.E., Cuttitta, F., and Walker, A., “Autocrine growth factors and solid tumor malignancy”, Western Journal of Medicine 155: 152-163, 1991.
Leban, et al., Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues, J Med Chem. Feb. 18, 1994;37(4):439-45.
Li, et al.; In-Vivo and In-Vitro Characterization of a Rh-105-Tetrathiamacrocycle Conjugate of a Bombesin Analogue, Proceedings of the 43rd Annual Meeting, vol. 37, No. 5, May 1996 Supplement, p. 61.
Zhu, et al.; Binding, internalization, and processing of bombesin by rat pancreatic acini, Bombesin Binding and Internalization, 1991, pp. G57-G64.
Moody, et al.; BW1023U90: A new GRP Receptor Antagonist for Small-Cell Lung Cancer Cells, Peptide

Affiliated with

Also associated with

Rating

Gastrin releasing peptide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gastrin releasing peptide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastrin releasing peptide compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2637292